On Dec. 14, 2020, CureVac announced that it had enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12 ﾵg. The study was expected to include more than 35,000 participants at sites in Europe and Latin America